Question special
Lead Moderator

The authors describe a 21-gene expression assay that provides additional prognostic information independent of clinicopathologic features of a breast cancer. It also predicts benefit from adjuvant chemotherapy in ER-positive disease.

Assuming the validity of the assay, what challenges are there in making this available to patients - in a hospital setting or privately?